For Penumbra's RED reperfusion catheters, should we emphasize increasing the product line's variety or improving the performance of existing models?

Introduction

The trade-off we're examining today is whether to emphasize increasing the product line's variety or improving the performance of existing models for Penumbra's RED reperfusion catheters. This decision is crucial for our product strategy and market positioning. I'll analyze this trade-off by considering user needs, market dynamics, and our business objectives.

Step 1

Clarifying Questions (3 minutes)

• Context: I'm thinking about the current market landscape for reperfusion catheters. Could you provide insights into our market share and main competitors?

Why it matters: Helps assess the competitive pressure and market opportunity. Expected answer: We're a top 3 player with 20-30% market share, facing strong competition. Impact: High competition would lean towards performance improvement, while market leadership might favor variety.

• Business Context: Based on our revenue model, I assume these catheters are a significant portion of our medical device portfolio. How does this product line contribute to our overall revenue and growth targets?

Why it matters: Aligns the decision with our financial objectives. Expected answer: RED catheters contribute 30-40% of revenue with high growth potential. Impact: High revenue contribution would justify more investment in either direction.

• User Impact: Considering the critical nature of these devices, I'm curious about user feedback. What are the primary pain points or requests from physicians using our catheters?

Why it matters: Ensures we're addressing actual user needs. Expected answer: Mix of requests for more specialized tools and improved performance in existing models. Impact: Would help balance between variety and performance improvement based on user priorities.

• Technical: Regarding our R&D capabilities, do we have any breakthrough technologies in development that could significantly enhance catheter performance?

Why it matters: Assesses our ability to make meaningful performance improvements. Expected answer: Some promising developments, but nothing revolutionary in the near term. Impact: Limited breakthrough potential might favor expanding variety over performance improvements.

• Resource: Considering our current team structure, how are our R&D resources allocated between new product development and existing product improvement?

Why it matters: Helps understand our capacity for pursuing either strategy. Expected answer: Currently split 60/40 between new development and improvement. Impact: Current allocation might influence which direction is more feasible without major restructuring.